Compound name: β-nicotinamide mononucleotide, reduced form, disodium salt
Molecular formula: C11H17N2O8P
Molecular weight: 336.24 g/mol
CAS No.: 108347-85-9
Dihydro nicotinamide mononucleotide (NMNH) is the reduced-form of nicotinamide mononucleotide (NMN), which was naturally occurred in kidney, act as a better NAD+ enhancer compared to NMN. NMNH could convert to NAD+ rapidly in vivo, which is two times higher than NMN in speed and concentration，and also increase the NAD+ level in a variety of tissues. NMNH could reduce cell damage under hypoxia condition by enhancing repair. In addition, Additionally, NMNH increased the NADH level in cells and in mouse liver, suppresses glycolysis and TCA cycle.
The world's leading Kosher-certified coenzyme manufacturer
In 2014, Bontac took the lead in realizing the industrialization of NMN
In 2021, Bontac achieve the world's first massive production of NMNH
Perfect quality control system
More than 40 high-precision imported testing equipment and dozens of testing indicators
Excellent green bio-enzyme catalytic synthesis technology platform
Unique enzymatic technology, Free acid type or sodium salt type of NMNH
Joint Research Centre with numerous internationally well-known universities
Provide high-quality research materials for more than 30 research institutions worldwide
Obtained more than 10 NMN related patents at home and abroad
Hundreds of independently developed enzyme catalysis-related invention patents and international patent applications
Always adhere to the whole-enzyme catalytic production, stable quality, high safety
Upgrade of coenzyme production line 3rd generation enzyme catalysis technology was implemented, Coenzyme production expand to annual output of 100 tons
